FDA Investigator Keith M Reilly

Keith M Reilly has inspections in 2 countries as of 31 Oct 2023. Keith M Reilly has collaborated with a combinined 3102 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
76
Last Inspection Date:
31 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
100008668
Country:
United States of America
Co-Investigator(s):
Addam S Reynolds, Alberto A Viciedo, Allen Lou, Amatul H Marium, Amy L Singer, Amy M Codella, Amy M Cramer, Ana S Cabrera, Ankur C Patel, Annemarie B Randow, Annemarie Bodnar, Anthony J Donato, Anthony M Criscuolo, Jr, Atul J Agrawal, Barbara J Maulfair, Barbara Jwilimczyk Macri, Brooke K Higgins, Bruce C Kovak, Byungja E Marciante, Cary Greene, Charles J Chacko, Charlotte P Chang, Chiang Syin, PhD, Christina N Maurino, Christine M Cerenzio, Clarice J Ahn, Craig W Swanson, Crystal A Harlan, Daniel J Grabicki, David H Smith, Deborah B Goffman, Deborah B Nixon, Deborah J Parris, Dennis L Doupnik, Devon Jenkins, Dhaval H Patel, Diane T Bargo, Diane T O'brien, Dianne H Milazzo, Donald L Lech, Douglas C Kovacs, Dr. Sriram Subramaniam, PhD, Edward D Mcdonald, Edward P Potter, Emest F Bizjak, Emmanuel J Ramos, Eric J Cunningham, Eric L Dong, BS, Eric Rothschild, Erin D Mccaffery, Ernest P Bizjak, Frank J Marciniak, Frederick Razzaghi, Gale L Glinecki, Gayle S Lawson, George M Ibrahim, Gianine E Delade, Gianine E Tompkins, Guerlain Ulysse, Helen B Ricalde, Helen Verdel, Hitesh R Patel, Jaison J Eapen, James W Leonette, Jason M Sluzynski, Jean M Kelahan, Jeffrey J Ebersole, Jeffrey J, Ebersole, Joey C West, Jogy George, John Dan, Jonee J Mearns, Jose M Cayuela, Joseph F Mcginnis, RPh, Joseph T Dougherty, Joseph W Matthews, Joy Rkozlowski Klena, Juanita P Versace, Karen A Briggs, Karen E D'orazio, Karen F Tomaziefski, Keith M Reilley, Kelli F Dobilas, Kelli F Regenye, Kelly Doremus, Kerry A Kurdilla, Kevin K Cole, King, Kinh Q Mac, Kristina J Donohue, Kristy A Zielny, Krystal O Ogunremi, L Zam Lam, Laishan L Lam, Lata C Mathew, PhD, Lawrence R Johnson, LCDR Anastasia Mpiliafas Brown, Li Li, Liatte Kreuger, PharmD, Lisa Harlan, Lori S Lawless, Marcellinus D Dordunoo, Marcelo O Mangalindan, Jr, Marcia D Fields, Marcus A Ray, Margaret M Sands, Maria Estrella, Marie T Falcone, Marjorie D Schultz, Matthew A Spataro, Melba Trivera Clavell, Melissa B Libby, Melissa J Garcia, Melissa T Roy, Mercedes Mota, Meredith L Sheridan, Merideth K Rose, Merril E Racke, Michael A Taylor, Michael F Skelly, PhD, Michael L Casner, Michael R Klapal, Michael Serrano, Miguel G Manzano, Monika Borkowska, Monique Rac Lester, Nancy F Scheraga, Nancy L Rolli, Nebil A Oumer, Nerizza B Guerin, Nicholas A Violand, Niketa Patel, Nora S Orrell, Parul M Patel, Paul L Bellamy, Peter R Lenahan, Philip F Istafanos, DMV, MS, Pratik S Upadhyay, DDC, Qin Xu, Rachel C Harrington, Raymond L Cheung, Remache, Richard D Manney, Richard H Penta, Robert G Ruff, Robert Sharpnack, Rodrigo Vilchez, Rose Ljean Mary, Roseline N Boateng, Russell J Glapion, Sarah Forney, Schultz, Sean D Duke, Sherri J Liu, Shirley S Wen, Sinai Davis, Stacey A Priest, State Agency, Stephanie L Shapley, Steven P Donald, Susan M Halsted, Suzanne M Healy, Suzanne M Muchene, Tania E Garcia, Tania E Vizcaino, Tara G Bizjak, Tara R Gooen, Tonia F Bernard, Toyin B Oladimeji, Tressa T Lewis, Valerie C Reed, Valerie Reed, Victoria Spivak, Walter L Fava, William J Muszynski, Willy A Orantes, Xikui Chen (nmi), PhD, Yvins Dezan, Zhongren Wu

Keith M Reilly's Documents

Publish Date Document Type Title
March, 2003 FDA 483 Ivax Pharmaceuticals Inc - Form 483, 2003-03-07
May, 2001 EIR SGS North America Inc. - EIR, 2001-05-23
May, 2001 FDA 483 Response SGS North America Inc. - Form 483R, 2001-06-15
June, 2001 FDA 483 Response McNeil PPC Inc. - Form 483R, 2001-06-28
June, 2003 EIR Carecam International, Inc. - EIR, 2003-06-09
June, 2003 FDA 483 Response Carecam International, Inc. - Form 483R, 2003-07-01
February, 2001 EIR BOC Group Inc, The - EIR, 2001-02-16
November, 2000 FDA 483 Response Novus Fine Chemicals - Form 483R, 2000-12-01
February, 2003 EIR MPL Laboratories - EIR, 2003-02-12
December, 2003 FDA 483 Response McNeil PPC Inc. - Form 483R, 2003-12-30
June, 2003 EIR Nutra-Med Packaging LLC - EIR, 2003-06-25
May, 2002 EIR ChemAid Laboratories, Inc. - EIR, 2002-05-10
June, 2001 EIR McNeil PPC Inc. - EIR, 2001-06-04
May, 2001 FDA 483 SGS North America Inc. - Form 483, 2001-05-23
May, 2002 FDA 483 ChemAid Laboratories, Inc. - Form 483, 2002-05-10
April, 2003 EIR Actavis Totowa LLC - EIR, 2003-04-25
December, 2003 FDA 483 McNeil PPC Inc. - Form 483, 2003-12-17
April, 2003 EIR Actavis Totowa LLC - EIR, 2003-04-25
July, 2003 FDA 483 Aphena Pharma Solutions - Form 483, 2003-07-10
November, 2001 EIR Frutarom USA Inc. - EIR, 2001-11-08
April, 2003 FDA 483 Actavis Totowa LLC - Form 483, 2003-04-25
November, 2000 EIR Novus Fine Chemicals - EIR, 2000-11-27
April, 2003 FDA 483 Response Actavis Totowa LLC - Form 483R, 2003-05-05
October, 2003 EIR Pharmachem Laboratories, Inc. - EIR, 2003-10-31
November, 2000 FDA 483 Novus Fine Chemicals - Form 483, 2000-11-27
April, 2003 FDA 483 Actavis Totowa LLC - Form 483, 2003-04-25
August, 2002 FDA 483 Bayer HealthCare LLC - Form 483, 2002-08-02
July, 2003 EIR Aphena Pharma Solutions - EIR, 2003-07-10
November, 2001 FDA 483 Frutarom USA Inc. - Form 483, 2001-11-08
February, 2002 EIR Suprema Specialties Inc - EIR, 2002-02-28
March, 2002 FDA 483 Sonar Products, Inc. - Form 483, 2002-01-02
December, 2003 EIR McNeil PPC Inc. - EIR, 2003-12-17
June, 2003 FDA 483 Carecam International, Inc. - Form 483, 2003-06-06
March, 2003 EIR Ivax Pharmaceuticals Inc - EIR, 2003-03-07
June, 2001 FDA 483 McNeil PPC Inc. - Form 483, 2001-06-04
October, 2003 FDA 483 Pharmachem Laboratories, Inc. - Form 483, 2003-10-31
September, 2004 FDA 483 Trigen Laboratories, Inc. - Form 483, 2004-09-02
July, 2003 EIR Goen Corporation - EIR, 2003-07-30
May, 2002 FDA 483 Response ChemAid Laboratories, Inc. - Form 483R, 2002-05-24

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more